A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Phase 3

Not yet recruiting

• Conditions: Small Cell Lung Cancer
• Interventions: Drug: AK112; Other: Placebo

• Registration Number: NCT07010263
• Lead Sponsor: Akeso

Brief Summary

This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-05-25
• Study Start: 2025-05-29
• Status Verified: 2025-06
• Study First Submitted QC: 2025-06-05
• Last Update Submitted: 2025-06-05
• Study First Posted: 2025-06-08
• Last Update Posted: 2025-06-08
• Primary Completion: 2028-12-31
• Study Completion: 2029-07-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 480

Inclusion Criteria

Inclusion Criteria:

1. The subjects voluntarily participated in the study with full informed consent and signed written informed consent form.
2. Aged ≥18 years on day fo signing the informed consent.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Life expectancy ≥ 3 months
5. Histologically or cytologically confirmed small cell lung cancer.
6. Documented limited-stage SCLC (Stage I-III SCLC [T any, N any, M0] according to the American Joint Committee on Cancer Staging Manual [AJCC Cancer Staging Manual, 8th Edition] or the Veterans Administration Lung Study Group (VALG) stage.
7. Have Received concurrent chemoradiotherapy regimen as defined in protocol and have not progressed following concurrent chemoradiotherapy.
8. Adequate organ function.
9. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.

Exclusion Criteria

1. Histologically or cytological confirmed the presence of mixed small cell lung cancer or non-small cell lung cancer components.
2. Toxicities from previous anti-tumor treatments have not resolved to grade 0 or 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or to the levels specified in inclusion/exclusion criteria, except for alopecia.
3. Symptoms or signs of primary disease deterioration that the investigator judges clinically unacceptable, such as cachexia.
4. Presence of pleural effusion, pericardial effusion, or ascites, which was clinically symptomatic or requiring frequent drainage.
5. History of active malignant tumors within the previous 5 years.
6. Received major surgery within 28 days prior to the first dose of study drug, or expected to undergo major surgery during the study period within 28 days after the first dose of study drug.
7. Uncontrolled comorbidities, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, and other related diseases..
8. Have serious neurological or mental illnesses, including dementia and epileptic seizures.
9. Pregnant or lactating women.
10. Have cardiovascular or cerebrovascular diseases or risk factors.
11. Prior treatments with systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration of the study drugs. Prior treatment with Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications within 1 weeks before the first administration of the study drugs.
12. Prior treatments targeting immune mechanisms, including, but not limited to, immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy.
13. Prior treatments with anti-angiogenic therapy.
14. Subjects requiring systemic treatment with corticosteroids (>10mg/day prednisone or equivalent dose) or other immunosuppressive drugs within 14 days prior to the first dose of study drug.
15. Known history of severe hypersensitivity reactions to other monoclonal antibodies or with a known history of allergy or hypersensitivity reactions to any of study drugs or their components.
16. Active autoimmune diseases that require systemic treatment within 2 years prior to the study, or autoimmune diseases that the investigator judges to be potentially recurrent or require planned treatment.
17. Known interstitial lung disease or non infectious pneumonia, which currently has symptoms or requires systemic corticosteroid treatment in the past,or investigator juges may affect the toxicity assessment or management related to the study treatment.
18. Known severe infection within 4 weeks prior to the first dose of study drug. Known active tuberculosis. Known active syphilis infection. Known history of immunodeficiency or positive HIV test results.
19. .Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
20. Active hepatitis B or active hepatitis C.
21. Received a live vaccine within 30 days prior to the first dose of study drug, or planning to receive a live vaccine during the study period.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ak112 arm	AK112	AK112 intravenous \[IV\]),every 3 weeks
Placebo arm	Placebo	Placebo intravenous \[IV\]),every 3 weeks

Primary Outcome Measures

Name	Time	Method
Progression-Free Survival(PFS) assessed by Blinded independent center review(BIRC)	Approximately 6 years	PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DOR) assessed by BICR per RECIST v1.1	Approximately 6 years
DOR assessed by investigator per RECIST v1.1	Approximately 6 years
DCR assessed by investigator per RECIST v1.1	Approximately 6 years
Overall Survival (OS)	Approximately 6 years	OS is defined as the time from randomization or first dosing to death due to any cause.
PFS assessed by investigator per RECIST v1.1	Approximately 6 years	PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1
Objective Response Rate (ORR) assessed by BICR Per RECIST v1.1	Approximately 6 years
ORR assessed by investigator Per RECIST v1.1	Approximately 6 years
Disease control rate(DCR) assessed by BICR per RECIST v1.1	Approximately 6 years
Number of participants with adverse event (AE)	Approximately 6 years	The number of participants experiencing an AE and the severity of AEs will be assessed. AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment.

Trial Locations

Locations (40)

Beijing Cancer Hospital; 🇨🇳 Beijing, Beijing, China

The First Medical Center of Chinese PLA General Hospital; 🇨🇳 Beijing, Beijing, China

Beijing Chest Hospital; 🇨🇳 Beijing, Beijing, China

Fujian Cancer Hospital; 🇨🇳 Fuzhou, Fujian, China

Longyan First Hospital; 🇨🇳 Longyan, Fujian, China

Zhangzhou Municipal Hospital of Fujian Province; 🇨🇳 Zhangzhou, Fujian, China

Jiangmen Central Hospital; 🇨🇳 Jiangmen, Guangdong, China

Liuzhou People's Hospital; 🇨🇳 Liuzhou, Guangxi, China

Affiliated Cancer Hospital of Guangxi Medical University; 🇨🇳 Nanning, Guangxi, China

The First Affiliated Hospital of Guangxi Medical University; 🇨🇳 Nanning, Guangxi, China

Scroll for more (30 remaining)